trending Market Intelligence /marketintelligence/en/news-insights/trending/SrJ6npit7c57DWZj0RAqog2 content esgSubNav
In This List

Trillium prices $30M common, preferred share offering

Blog

Japan M&A By the Numbers: Q4 2023

Blog

Essential IR Insights Newsletter Fall - 2023

Case Study

A Corporation Clearly Pinpoints Activist Investor Activity

Blog

Insight Weekly: Bank mergers of equals return; energy tops S&P 500; green bond sales to rise


Trillium prices $30M common, preferred share offering

Trillium Therapeutics Inc. priced an underwritten public offering of 2,750,000 common shares and 3,250,000 series II preferred shares at $5 apiece.

The company also granted underwriters a 30-day option to buy up to an additional 412,500 common shares. The offering is expected to close June 1.

Gross proceeds from the offering are expected to be about $30 million. Trillium plans to use the net proceeds for phase 1 trials of TTI-621 for the treatment of certain type of cancers.

Cowen is acting as the sole book-running manager for the offering while Ladenburg Thalmann is acting as co-manager.